RedHill Biopharma Ltd. (RDHL)
USD 2.31
(11.35%)
USD 2.31
(11.35%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 12.63 Million USD | 26.83% |
| 2022 | -42.84 Million USD | 47.19% |
| 2021 | -81.13 Million USD | -27.4% |
| 2020 | -63.68 Million USD | -47.41% |
| 2019 | -43.2 Million USD | -9.84% |
| 2018 | -39.33 Million USD | 24.32% |
| 2017 | -51.97 Million USD | -70.16% |
| 2016 | -30.54 Million USD | -38.82% |
| 2015 | -22 Million USD | -106.65% |
| 2014 | -10.64 Million USD | 1.16% |
| 2013 | -10.77 Million USD | -19.16% |
| 2012 | -9.04 Million USD | -14.82% |
| 2011 | -7.87 Million USD | -354.3% |
| 2010 | -1.73 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q2 | -4.4 Million USD | -108.7% |
| 2023 Q1 | 50.66 Million USD | 609.27% |
| 2023 FY | -31.35 Million USD | 26.83% |
| 2022 Q3 | -7.1 Million USD | 22.39% |
| 2022 Q1 | -13.23 Million USD | 36.05% |
| 2022 Q2 | -9.15 Million USD | 30.81% |
| 2022 FY | -42.84 Million USD | 47.19% |
| 2022 Q4 | -9.94 Million USD | -39.95% |
| 2021 Q2 | -24.88 Million USD | -37.1% |
| 2021 Q3 | -17.39 Million USD | 30.09% |
| 2021 Q4 | -20.69 Million USD | -18.97% |
| 2021 FY | -81.13 Million USD | -27.4% |
| 2021 Q1 | -18.15 Million USD | 7.9% |
| 2020 FY | -63.68 Million USD | -47.41% |
| 2020 Q1 | -17.01 Million USD | -44.64% |
| 2020 Q2 | -12.5 Million USD | 26.54% |
| 2020 Q3 | -14.46 Million USD | -15.68% |
| 2020 Q4 | -19.7 Million USD | -36.29% |
| 2019 Q3 | -9.84 Million USD | 20.48% |
| 2019 Q1 | -9.21 Million USD | 8.26% |
| 2019 Q2 | -12.38 Million USD | -34.38% |
| 2019 FY | -43.2 Million USD | -9.84% |
| 2019 Q4 | -11.76 Million USD | -19.5% |
| 2018 FY | -39.33 Million USD | 24.32% |
| 2018 Q4 | -10.04 Million USD | -3.15% |
| 2018 Q3 | -9.73 Million USD | -1.87% |
| 2018 Q2 | -9.55 Million USD | 4.38% |
| 2018 Q1 | -9.99 Million USD | 30.43% |
| 2017 Q3 | -13.96 Million USD | -3.15% |
| 2017 Q4 | -14.36 Million USD | -2.87% |
| 2017 FY | -51.97 Million USD | -70.16% |
| 2017 Q2 | -13.53 Million USD | -34.02% |
| 2017 Q1 | -10.1 Million USD | -12.34% |
| 2016 FY | -30.54 Million USD | -38.82% |
| 2016 Q4 | -8.99 Million USD | -6.36% |
| 2016 Q3 | -8.45 Million USD | -17.51% |
| 2016 Q2 | -7.19 Million USD | -21.87% |
| 2016 Q1 | -5.9 Million USD | 12.74% |
| 2015 Q1 | -4.75 Million USD | 1.23% |
| 2015 FY | -22 Million USD | -106.65% |
| 2015 Q4 | -6.76 Million USD | -47.32% |
| 2015 Q3 | -4.59 Million USD | 22.04% |
| 2015 Q2 | -5.89 Million USD | -23.87% |
| 2014 FY | -10.64 Million USD | 1.16% |
| 2014 Q4 | -4.81 Million USD | 3.93% |
| 2014 Q2 | -4.11 Million USD | -224.97% |
| 2014 Q1 | 3.29 Million USD | 194.6% |
| 2014 Q3 | -5.01 Million USD | -21.8% |
| 2013 FY | -10.77 Million USD | -19.16% |
| 2013 Q2 | -2.52 Million USD | -25.24% |
| 2013 Q1 | -2.01 Million USD | 4.63% |
| 2013 Q3 | -2.74 Million USD | -8.83% |
| 2013 Q4 | -3.48 Million USD | -26.59% |
| 2012 Q4 | -2.11 Million USD | -9.81% |
| 2012 Q1 | -2.93 Million USD | -19.28% |
| 2012 Q3 | -1.92 Million USD | 6.78% |
| 2012 Q2 | -2.06 Million USD | 29.56% |
| 2012 FY | -9.04 Million USD | -14.82% |
| 2011 FY | -7.87 Million USD | -354.3% |
| 2011 Q3 | -2.21 Million USD | 0.0% |
| 2011 Q4 | -2.45 Million USD | -10.97% |
| 2010 FY | -1.73 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 92.434% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 602.223% |
| Embecta Corp. | 221.5 Million USD | 94.297% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 85.592% |
| PainReform Ltd. | -9.58 Million USD | 231.803% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 363.975% |
| SCYNEXIS, Inc. | 72.66 Million USD | 82.617% |
| Journey Medical Corporation | -2.07 Million USD | 709.358% |
| Safety Shot Inc | -12.18 Million USD | 203.676% |
| Alpha Teknova, Inc. | -35.56 Million USD | 135.52% |
| Bright Green Corporation | -8.89 Million USD | 242.07% |
| Procaps Group, S.A. | 38.97 Million USD | 67.588% |
| Alvotech | -354.86 Million USD | 103.56% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 73.107% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 183.645% |
| Cosmos Health Inc. | -21.83 Million USD | 157.862% |
| Dynavax Technologies Corporation | -37.02 Million USD | 134.115% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 108.12% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 107.926% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 363.975% |
| Theratechnologies Inc. | -10.62 Million USD | 218.867% |
| Harrow Health, Inc. | 580 Thousand USD | -2077.931% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 368.709% |
| Biofrontera Inc. | -22.67 Million USD | 155.704% |
| DURECT Corporation | -36.88 Million USD | 134.248% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 339.742% |
| Cronos Group Inc. | -81.37 Million USD | 115.523% |
| OptiNose, Inc. | -22.74 Million USD | 155.53% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 93.957% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 132.263% |
| Organogenesis Holdings Inc. | 12.52 Million USD | -0.854% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | 391.307% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 303.387% |
| Radius Health, Inc. | -3.92 Million USD | 421.834% |
| Universe Pharmaceuticals INC | -3.52 Million USD | 458.174% |
| ProPhase Labs, Inc. | -21.61 Million USD | 158.446% |
| Phibro Animal Health Corporation | 53.31 Million USD | 76.307% |
| Procaps Group S.A. | 52.32 Million USD | 75.858% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 248.211% |
| Viatris Inc. | 766.2 Million USD | 98.351% |
| Rockwell Medical, Inc. | -6.67 Million USD | 289.385% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 340.426% |
| SIGA Technologies, Inc. | 83.62 Million USD | 84.894% |
| Tilray Brands, Inc. | -174.74 Million USD | 107.229% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | -35.377% |
| Shineco, Inc. | -17.06 Million USD | 174.019% |
| PetIQ, Inc. | 60.01 Million USD | 78.952% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 366.682% |
| Incannex Healthcare Limited | -30.04 Million USD | 142.049% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 94.965% |
| Alimera Sciences, Inc. | -1.47 Million USD | 958.736% |
| Silver Spike Investment Corp. | 7.34 Million USD | -72.096% |
| Assertio Holdings, Inc. | -243.53 Million USD | 105.187% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 314.379% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 192.764% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 181.006% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 163.002% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 109.164% |
| Hempacco Co., Inc. | -8.81 Million USD | 243.345% |
| Talphera, Inc. | -16.88 Million USD | 174.794% |
| Alvotech | -354.86 Million USD | 103.56% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 76.368% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 96.536% |
| Currenc Group, Inc. | -6.64 Million USD | 290.075% |
| Kamada Ltd. | 10.06 Million USD | -25.517% |
| Indivior PLC | -4 Million USD | 415.8% |
| Evoke Pharma, Inc. | -7.43 Million USD | 269.993% |
| Flora Growth Corp. | -50.35 Million USD | 125.086% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 163.002% |
| Evolus, Inc. | -49.23 Million USD | 125.658% |
| HUTCHMED (China) Limited | 18.37 Million USD | 31.254% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 93.587% |
| Akanda Corp. | -10.05 Million USD | 225.674% |